High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation

• Published in: Human immunology 2012-04, Vol.73 (4), p.382-388
• Main Authors: Sjöwall, Christopher, Cardell, Kristina, Boström, Elisabeth A, Bokarewa, Maria I, Enocsson, Helena, Ekstedt, Mattias, Lindvall, Liselott, Frydén, Aril, Almer, Sven
• Format: Article
• Language: English
• Subjects: Adult; Aged; Allergy and Immunology; Autoantibodies; Autoantibodies - immunology; C-reactive protein; C-Reactive Protein - immunology; Female; Follow-Up Studies; Hepacivirus - genetics; Hepatitis C; Hepatitis C, Chronic - epidemiology; Hepatitis C, Chronic - immunology; Hepatitis C, Chronic - pathology; Humans; Immunologi inom det medicinska området; Immunology in the medical area; Inflammation - immunology; Interferon-alpha; Interferon-α; Liver Cirrhosis - immunology; Liver Cirrhosis - pathology; Male; MEDICIN; MEDICINE; Middle Aged; Portal System - immunology; Portal System - pathology; Prognosis; Resistin; Resistin - blood; Retrospective Studies; Seroepidemiologic Studies
• ISSN: 0198-8859; 1879-1166; 1879-1166
• DOI: 10.1016/j.humimm.2012.01.009

Abstract The presence of autoantibodies against C-reactive protein (anti-CRP) has been reported in association with autoimmunity and histopathology in chronic hepatitis C virus (HCV) infection. Resistin could play a role in the pathogenesis of hepatitis, although results on HCV infection are ambiguous. Here we retrospectively analyzed anti-CRP and resistin levels in the sera of 38 untreated and well-characterized HCV patients at the time of their first liver biopsy. HCV activity and general health were assessed by a physician at least yearly until follow-up ended. Anti-CRP and resistin were also measured in patients with autoimmune hepatitis (AIH) and nonalcoholic fatty liver disease (NAFLD). Anti-CRP antibodies were registered in all HCV patients, whereas only a few AIH (11%) and NAFLD (12%) sera were positive. Anti-CRP levels were related to histopathological severity and were highest in patients with cirrhosis at baseline. Resistin levels were similar in HCV, AIH, and NAFLD patients, but high levels of resistin were associated with early mortality in HCV patients. Neither anti-CRP nor resistin predicted a response to interferon-based therapy or cirrhosis development or was associated with liver-related mortality. We conclude that anti-CRP antibodies are frequently observed in chronic HCV infection and could be a useful marker of advanced fibrosis and portal inflammation.